Introduction
============

Psoriasis, as characterized by a well-demarcated erythematous plaque with silver scales, is a chronic, immune-mediated disorder that mainly affects the skin and joints ([@b1-mmr-20-01-0225]). The worldwide prevalence rates of psoriasis range from 0.9--8.5% in adults and 0--2.1% in children ([@b2-mmr-20-01-0225]). Although this condition rarely poses a threat to life, the irritation, pain and especially the aberrant appearance make these patients susceptible to psychological problems, such as anxiety and depression ([@b3-mmr-20-01-0225],[@b4-mmr-20-01-0225]). With recent advances in the understanding of psoriasis, an increasing number of therapies have emerged, however a high recurrence rate persists. Therefore, it is important to better understand the underlying molecular pathogenesis of psoriasis in order to identify more effective therapeutic approaches for the control of psoriasis development and progression.

Gene expression microarrays have been widely applied in psoriatic research and represent an important new tool for use in the identification of disease-related molecules associated with psoriasis. Recently, comprehensive analysis of microarray data from multiple centers has become a popular research area. Ainali *et al* investigated gene expression patterns in lesional and non-lesional psoriatic tissue samples from 2 GEO data sets to establish a molecular sub-groups within the clinical phenotype of plaque psoriasis ([@b5-mmr-20-01-0225]). Mei and Mei screened differentially expressed genes based on 4 psoriatic data sets followed by characterization of gene functions and mutual interactions ([@b6-mmr-20-01-0225]). Sevimoglu and Arga analyzed and integrated data from 12 studies to identify the potential candidates for disease biomarkers and therapeutic targets ([@b7-mmr-20-01-0225]).

However, analysis of the unpaired data obtained from lesional and non-lesional samples may lead to a potential bias caused by disease heterogeneity. In order to eliminate or reduce such bias, only paired lesional and the corresponding non-lesional skin samples were selected and analyzed in this study. Information was compiled from 5 original microarray data sets, GSE14905 ([@b8-mmr-20-01-0225]), GSE30999 ([@b9-mmr-20-01-0225],[@b10-mmr-20-01-0225]), GSE34248 ([@b11-mmr-20-01-0225]), GSE41662 ([@b11-mmr-20-01-0225]) and GSE53552 ([@b12-mmr-20-01-0225]), from the Gene Expression Omnibus (GEO) database. A total of 175 pairs of lesional and non-lesional skin samples from plaque psoriatic patients were selected. With use of bioinformatic methods, integrated differentially expressed genes (DEGs) were identified, followed by the Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Protein-protein interaction (PPI) analysis and hug gene calculation were subsequently performed. Finally, an additional GEO data set, GSE75343 ([@b13-mmr-20-01-0225]), which contained a study of gene expression levels in scalp psoriatic patients, was used as a means to validate whether the hub genes obtained from the aforementioned databases exhibited a similar expression profile as that in scalp psoriatic lesions.

Through integration of the bioinformatic analyses of the gene expression from these 175 pairs of psoriatic skin samples, 377 genes were identified as DEGs, with 277 of these genes being upregulated and 96 genes downregulated. We revealed that these genes covered a wide range of biological functions in epidermal development, keratinization, immune responses, metabolic pathways, cell cycle and extracellular spaces. These results provide a comprehensive understanding of the molecular pathogenesis of the disease, which may guide subsequent studies on psoriasis research.

Materials and methods
=====================

### Microarray data sets and data calibration

Using the keyword 'psoriasis', data sets using the descriptors 'paired biopsy from both lesional and non-lesional skin' and 'pre-treatment status' were screened. The raw files of 5 enrolled microarray data sets, including GSE14905 ([@b8-mmr-20-01-0225]), GSE30999 ([@b9-mmr-20-01-0225],[@b10-mmr-20-01-0225]), GSE34248 ([@b11-mmr-20-01-0225]), GSE41662 ([@b11-mmr-20-01-0225]) and GSE53552 ([@b12-mmr-20-01-0225]) ([Table I](#tI-mmr-20-01-0225){ref-type="table"}), were downloaded from the NCBI GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). In each data set, only pre-treatment psoriatic skin samples and their matched adjacent normal samples were selected, which resulted in 175 pairs of skin samples from psoriatic patients for subsequent analysis. The raw files were processed with R software 3.5.1 (<https://www.r-project.org>) to convert the gene probe IDs to gene symbol codes. Finally, calibrations of gene expression levels according to the quartile method were performed for subsequent analysis.

### DEGs analysis and integration

A differential expression analysis on each GEO series, as based on paired-sample t-tests between psoriatic skin and adjacent normal skin samples, were performed with use of R software. A gene was defined as a differentially expressed gene between the psoriatic and normal sample when the P-value was \<0.05 (P\<0.05) and the gene expression fold change (FC) value was \>2 or \<0.5 (\|log2FC\|≥1), which were illustrated as Volcano plots. An overlap of total, upregulated or downregulated DEGs, plotted as Venn charts, from all 5 data sets were listed for subsequent function analysis.

### GO term and KEGG pathway analysis of DEGs

The DAVID knowledgebase (<https://david.ncifcrf.gov/>), an online gene functional annotation tool, was used to analyze the function and pathway enrichment of candidate genes obtained ([@b14-mmr-20-01-0225]). With this technique, the Fisher exact test P-value was calculated as a result of enrichment degree. The top 10 enrichment GO term or KEGG pathway annotations for both up- or downregulated DEGs obtained in our study were listed.

### PPI network and hub gene analyses

The STRING platform, an online tool used for the structural and functional analysis of protein interactions ([@b15-mmr-20-01-0225]), was used to identify interactions among proteins of interest. The corresponding results were analyzed and structured with the use of the Cytoscape software 3.6.1 (<https://cytoscape.org>). The hub genes, which were considered to be involved in playing pivotal regulatory roles in the PPI network, were subsequently calculated based on the overlapping results obtained by MCC (Maximal Clique Centrality) and DMNC (Density of Maximum Neighborhood Component) topological analysis methods, respectively, with use of the cytoHubba app built in the software ([@b16-mmr-20-01-0225]).

### GEO2R analysis of gene expression levels

The gene expression levels of hub genes were analyzed in GSE75343 ([@b13-mmr-20-01-0225]), a microarray data set comparing gene expression levels of scalp psoriatic skin and adjacent normal skin samples ([Table I](#tI-mmr-20-01-0225){ref-type="table"}). The GEO2R, an online analysis tool built in the GEO website, was used for this analysis. Statistical analyses were performed using paired-sample t-tests and a P-value \<0.05 was required for results to be considered statistically significant. Scatter charts were plotted using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

### Microarray data standardization and DEG identification in plaque psoriasis

With use of the quartile division method, gene expression levels of each of the 5 GEO series were standardized and the results of pre- and post-standardization are presented in [Fig. 1A](#f1-mmr-20-01-0225){ref-type="fig"}. After pre-processing of the data, DEGs were analyzed using paired-sample t-tests within each series using a screening criteria of P\<0.05 and \|log2FC\|≥1 ([Fig. 1B](#f1-mmr-20-01-0225){ref-type="fig"}). The number of DEGs in each series, including up- and downregulated DEGs are presented in [Table II](#tII-mmr-20-01-0225){ref-type="table"}. When DEGs in each series were intersected with one another, 373 genes, considered as integrated DEGs were obtained and used for subsequent analysis with 277 of these genes being upregulated and 96 downregulated ([Fig. 2](#f2-mmr-20-01-0225){ref-type="fig"}). The ratio of the number of upregulated genes to that of downregulated genes was close to 1:1 in each of the GEO data sets, however, in the integrated results this ratio was equal to approximately 3:1, indicating a possible commonality in the upregulated genes during psoriasis development while the downregulated genes differ in individuals.

### GO and KEGG pathway enrichment analysis of DEGs

GO enrichment analysis, which is comprised of 3 functional groups (biological processes, cellular components and molecular functions), was performed using the DAVID online tool. Within each of the functional groups, the top 10 enrichment terms for both up- or downregulated DEGs as identified according to the Fisher\'s exact test P-value are listed in [Tables III](#tIII-mmr-20-01-0225){ref-type="table"} and [IV](#tIV-mmr-20-01-0225){ref-type="table"}. The corresponding visual diagrams are presented in [Fig. 3A and B](#f3-mmr-20-01-0225){ref-type="fig"}. Within the biological process function group, upregulated DEGs were mainly enriched in GO terms of immune responses, ectoderm development, defense responses, keratinization and epidermal development while downregulated DEGs were mainly enriched in the regulation of system processes, regulation of smooth muscle contraction and muscle organ development. Notably, with the exception of enrichment of the cornified envelope, which is an extremely tough structure formed beneath the cell membrane ([@b17-mmr-20-01-0225]) in the upregulated DEGs group, both up- and downregulated DEGs were enriched in the extracellular space within the cellular component enrichment analysis. Within the molecular function enrichment group, the upregulated DEGs were mainly enriched in chemokine activity, chemokine receptor binding and endopeptidase inhibitor activity, while downregulated DEGs were enriched in cytoskeletal protein binding processes. The KEGG pathway enrichment was performed using the same analysis tool and the results, in which only the pathways for the upregulated genes are displayed by figure, due to the limited number of enrichment pathways in the downregulated group, are presented in [Table V](#tV-mmr-20-01-0225){ref-type="table"} and [Fig. 4](#f4-mmr-20-01-0225){ref-type="fig"}. In upregulated DEGs, signaling pathways were mainly enriched in metabolic pathways, measles, influenza A and chemokine signaling pathways, while aldosterone-regulated sodium reabsorption and PPAR signaling pathways were enriched in downregulated DEGs.

### PPI network construction and hub gene selection

The online database STRING was used to obtain PPI information on the 373 DEGs, including the 277 upregulated and 96 downregulated genes and the PPI network, with 2 notable functional modules, was constructed with use of Cytoscape software ([Fig. 5A](#f5-mmr-20-01-0225){ref-type="fig"}). Hub genes were then calculated using the cytoHubba app from the network we constructed. As a result of these calculations, 17 genes with the highest scores were considered as hub genes and were automatically divided into 2 groups exactly corresponding to the modules in [Fig. 5A](#f5-mmr-20-01-0225){ref-type="fig"}. One group consisted of *TTK, AURKA, DLGAP5, HMMR, CDC45, CENPE, SPC25, MCM10, NDC80, RRM2, CKS2* and *NUF2*, which are genes involved in the cell cycle, mitosis and proliferation. The second group consisted of *IFI6, ISG20, IFIT1, RSAD2* and *IFI27*, all of which belong to IFN-α-inducible genes ([Fig. 5B](#f5-mmr-20-01-0225){ref-type="fig"}). Notably, these 17 hub genes all belong to the upregulated genes of the DEGs we obtained, which further demonstrated the importance of these upregulated genes in the molecular pathogenesis of psoriasis.

### Hub gene expression levels in scalp psoriasis

To investigate whether scalp psoriasis displayed a similar gene expression profile as that of skin psoriasis, 13 pairs of scalp lesional and adjacent non-lesional samples were selected from GSE75343 ([Table I](#tI-mmr-20-01-0225){ref-type="table"}). With use of the online analysis tool, GEO2R, expression levels of these 17 hub genes were determined. The results revealed that statistically significant differences were obtained in the expression of *IFI6, IFI27, RSAD2, ISG20, MCM10* and *SPC25* ([Fig. 6](#f6-mmr-20-01-0225){ref-type="fig"}), but not in the other hub genes (data not shown). Further analysis revealed that 4 out of 6 IFN-α-inducible genes exhibited significant differences with regard to gene expression, while in genes involved in the cell cycle, mitosis and proliferation, only 2 of them exhibited differences in gene expression.

Discussion
==========

Psoriasis, one of the most common skin ailments, afflicts millions of people worldwide. In addition to its negative aspects on physical and mental health, the cost of psoriasis places a huge burden on both individuals and society ([@b17-mmr-20-01-0225]). Although dozens of medications are available for relief of the symptoms of this disease, no cure for psoriasis currently exists. Therefore, it is clear that the identification of pivotal molecules that play critical roles in the pathogenesis of this disease for potential development of therapeutic targets represents an important area of investigation.

Gene expression microarrays provide a comprehensive view of genome-wide expression profiles of clinical samples and have been widely used to analyze genes which are differentially expressed in psoriasis. However, few studies exist which have integrated such high-throughput gene expression microarray data of paired lesional and non-lesional skin samples. In the present study, gene expression profiles of 175 pairs of psoriatic skin samples and the corresponding normal tissues from 5 GEO data sets were integrated and analyzed with use of bioinformatic methods. Our results demonstrated several important pathways and the pivotal genes associated with the molecular pathogenesis of psoriasis.

Psoriasis is an immune-mediated inflammatory cutaneous disease characterized by an overt proliferation and differentiation of keratinocytes ([@b1-mmr-20-01-0225]). Our GO biological process enrichment results, especially with regard to upregulated genes, included immune responses, keratinization, inflammatory responses and keratinocyte differentiation, all of which are commonly accepted components of the pathogenesis and pathological changes of psoriasis. In addition, the enrichment in defense responses and responses to wound healing processes indicates two important psoriatic precipitating factors: infection ([@b18-mmr-20-01-0225]) and trauma (Koebner phenomena) ([@b19-mmr-20-01-0225]), respectively, both of which are associated with the activation of innate immunity involved in the initial pathogenesis of psoriasis ([@b20-mmr-20-01-0225]). Additional reported risk factors include smoking ([@b21-mmr-20-01-0225]), alcohol ([@b22-mmr-20-01-0225]) and obesity ([@b23-mmr-20-01-0225]). In the cellular component enrichment analysis, in addition to mitosis-associated components such as chromosome kinetochore and the Ndc80 complex, enrichment in the extracellular matrix of both up- or downregulated genes revealed the significance of this component. The extracellular matrix (ECM) is a collection of non-cellular molecular networks that regulate diverse cellular functions, such as growth, migration and homeostasis ([@b24-mmr-20-01-0225],[@b25-mmr-20-01-0225]). The ECM is composed of interstitial matrix and basement membrane, both of which are reported to be involved in the development of psoriasis. Findings from a guttate psoriasis prognosis study, indicate that psoriasis disease progression is believed to be governed by the triggering of humoral immune responses, which could produce extracellular antibodies to neutralize the streptococcal lytic enzyme and prevent disruption of the laminin layer in the basement membrane caused by the enzyme ([@b26-mmr-20-01-0225]). Recently, neutrophil extracellular traps (NETs), which are web-like structures consisting of DNA associated with histones, antimicrobial peptides and enzymes ([@b27-mmr-20-01-0225],[@b28-mmr-20-01-0225]), were reported to act as a source of autoantigens which contribute to the occurrence of several autoimmune diseases ([@b29-mmr-20-01-0225],[@b30-mmr-20-01-0225]), including psoriasis. For example, Lin *et al* reported that mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis ([@b31-mmr-20-01-0225]). In molecular function enrichment analysis, it was observed that in upregulated genes, several GO terms indicated endopeptidase inhibitor activity, which contains a family of serine protease inhibitors (serpins). Serpins, such as *SERPINA3, SERPINB4, SERPINA1, SERPINB12, SERPINB3* and *SERPINB13* in our enrichment gene list represent a broad family of protease inhibitors that utilize conformational changes to inhibit target enzymes ([@b32-mmr-20-01-0225]); and it has been suggested that these serpins play a role in psoriatic pathogenesis. Similar to the results obtained in our analysis, Johnston *et al* detected upregulation of two endogenous protease inhibitors, serpins A1 and A3, both of which are present in psoriasis vulgaris and generalized pustular psoriasis. These serpins may play a counter-regulated role to control the activity of IL-36, whose activation requires N-terminal peptide cleavage by neutrophil serine protease ([@b33-mmr-20-01-0225]). Such a negative regulatory effect, although unlikely to balance the protease expression revealed in the study by Lin *et al* ([@b31-mmr-20-01-0225]), may provide for new insights into the development of psoriasis therapy.

The results from our KEGG pathway analysis revealed that a high enrichment in metabolic and viral infection pathways was present in upregulated genes. There were 26 genes enriched in metabolic pathways, including *XDH, GDA, KYNU, HSD17B2, NT5C3A, GALNT6, CYP2C18, UPP1, AASS, PNP, CMPK2, ARG1, TYMP, HPSE, ALOX12B, FUT2, SPTLC2, DHRS9, HYAL4, ST6GALNAC1, SQLE, RRM2, AKR1B10, LIPG, GK, SMPD3* and *PLA2G4D*. Among these genes, *ALOX12B*, one of the lipoxygenases, is reported to play an important role in the regulation of epithelial proliferation, differentiation, wound healing and inflammatory skin diseases ([@b34-mmr-20-01-0225]). *PLA2G4D*, a member of phospholipase A2, was revealed to have a strong gene expression in the upper spinous layer of psoriatic epidermis, while in normal skin the expression of *PLA2G4D* was not detected ([@b35-mmr-20-01-0225]). The expression or functions of the other genes in our list have received little attention with regard to their roles in cutaneous disorders. Therefore, these genes may provide important new research targets for the understanding and treatment of psoriasis. Most of the genes enriched in viral infection KEGG pathways are IFN-α-inducible genes which belong to one group of the hub genes in the PPI network.

The PPI network was constructed by Cytoscape software and hub genes were then determined. With this analysis, 17 genes were identified and divided into 2 groups according to protein-protein interactions. One group of these were IFN-α-inducible genes, which were also enriched in KEGG viral infection pathways, and included *IFI6, IFI27, IFIT1, RSAD2* and *ISG20*. A role for IFN-α in psoriasis development has been gradually revealed. For example, Garcia-Romo *et al* demonstrated that in the initial phase of disease development, cutaneous accumulated plasmacytoid pre-dendritic cells become activated and produce IFN-α, which then drives the stimulation of autoimmune T cells in pre-psoriatic skin ([@b30-mmr-20-01-0225]). Such a mechanism provides an explanation for the role of innate immunity in connecting environmental triggers, such as viral or bacterial infection and wound healing with disease-associated autoimmune T cells. This also clarifies the reason for an absence of IFN-α in our analysis, since the samples we selected were all from chronic plaque psoriasis patients. The expression of IFN-α-inducible genes in our study was also observed in scalp psoriatic samples, demonstrating an important role for IFN-α in the pathogenesis of psoriasis within different skin areas. The other group of genes including, *CSK2, CDC45, MCM10, SPC25, NDC80, NUF2, AURKA, CENPE, RRM2, DLGP5, HMMR* and *TTK*, were associated with the regulation of the cell cycle, mitosis and proliferation ([@b36-mmr-20-01-0225],[@b37-mmr-20-01-0225]). Notably, there are two kinases in this group of hub genes: Aurora kinase A, essential for chromosome segregation ([@b38-mmr-20-01-0225]) and TTK, whose expression is at high levels in tissues which contain large numbers of proliferating cells ([@b39-mmr-20-01-0225]). While the relationship between these kinases and psoriasis development is yet unclear, there exists a potentially important role that they may play in the pathogenesis of psoriasis. In contrast to the results in the IFN-α-inducible gene group, the expression of most hub genes associated with the cell cycle and proliferation in scalp psoriatic samples (except for *MCM10* and *SPC25*), revealed no significant differences from that of paired control samples. Within the scalp area a large proportion of follicles are in anagen, which may contribute to a set of highly expressed genes associated with the cell cycle and proliferation. This can be contrasted with that of skin samples from other areas where most hair follicles are in catagen or telophase. Histologically, in the initial stages of this disease scalp psoriasis mainly affects the interfollicular epidermis with perifollicular inflammation ([@b13-mmr-20-01-0225]), while later stages include destruction of hair follicles with perifollicular fibrosis and hair loss ([@b40-mmr-20-01-0225]). Based on these findings, it was hypothesized that the expression of these cell cycle-related genes, which are assumed to be at high expression levels in psoriatic samples, is relatively reduced in scalp psoriatic samples where hair follicle destruction occurs as compared to normal scalp tissues, as reflected in our results.

Although a similar bioinformatical study on psoriasis has been performed ([@b7-mmr-20-01-0225]), in our present study, we limited our data sets to paired lesional and non-lesional psoriatic skin samples and performed DEG analysis with use of paired-sample t-tests in each data set. An overlap method was subsequently employed to combine these DEG results as a means to obtain an overall set of DEGs corresponding with that of each data set. With use of these strict screening methods, we consider that our results have a relatively high degree of specificity for detecting pivotal disease-associated molecules, however the resultant low sensitivity would be considered as a limitation of this study. In our future research, if ethical approval is obtained, RT-qPCR validation of these identified target genes in clinical samples will be conducted. In conclusion, through a comprehensive bioinformatic re-analysis of these original GEO data, an overall view regarding the molecular pathogenesis of psoriasis and the potential for identification of therapeutic targets for this disease was provided.
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![Data standardization and DEG identification. (A) Pre-standardization gene expression levels of each data set are presented as blue boxplots and post-standardization values are presented as purple boxplots. (B) The upregulated DEGs (red dots) and downregulated DEGs (green dots) of each data set were identified with the use of criteria of P\<0.05 and \|log2FC\|≥1. DEGs, differently expressed genes.](MMR-20-01-0225-g00){#f1-mmr-20-01-0225}

![DEG integration of each data set. DEGs of each data set are overlapped and presented as a Venn plot, including total, upregulated and downregulated genes. DEGs, differently expressed genes.](MMR-20-01-0225-g01){#f2-mmr-20-01-0225}

![GO enrichment of DEGs. (A) GO enrichment of upregulated DEGs in 3 functional groups: biological processes (red), cellular components (green) or molecular functions (blue). These groups are ranked and presented as bar plots according to their Fisher\'s exact P-value. (B) GO enrichment of downregulated DEGs. DEGs, differently expressed genes; GO, gene ontology.](MMR-20-01-0225-g02){#f3-mmr-20-01-0225}

![KEGG pathway enrichment of upregulated DEGs. The upregulated DEGs were mainly enriched in metabolic and viral infection KEGG pathways. Rich factor (%) is the ratio of the number of differentially expressed genes annotated in a pathway (as indicated in the y-axis) to the number of all genes annotated in this pathway. DEGs, differently expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-20-01-0225-g03){#f4-mmr-20-01-0225}

![PPI network and hub genes. (A) The PPI network was constructed and formatted with upregulated genes revealed in red ellipses and downregulated genes in green ellipses. (B) Hub genes, represented as circles, were separated into 2 groups and the interaction evidence degree between proteins is presented as the gray scale of the lines. PPI, protein-protein interaction.](MMR-20-01-0225-g04){#f5-mmr-20-01-0225}

![Gene expression levels in scalp psoriasis. Hub genes with significantly different expression levels between lesional and non-lesional scalp samples are plotted. The asterisk (\*) indicates statistically significant differences between non-lesional scalp and lesional scalp samples (\*P\<0.05, \*\*P\<0.01).](MMR-20-01-0225-g05){#f6-mmr-20-01-0225}

###### 

Information for psoriatic GEO data.

  GEO series   Platform   Sample                          Type                                                         Pair no.   (Refs.)
  ------------ ---------- ------------------------------- ------------------------------------------------------------ ---------- -----------------------------------------------
  GSE14905     GPL570     Paired LS and NLS               Plaque psoriasis                                             28         Yao *et al* ([@b8-mmr-20-01-0225])
  GSE30999     GPL570     Paired LS and NLS               Moderate to severe plaque psoriasis                          85         Suárez-Fariñas *et al* ([@b9-mmr-20-01-0225])
  GSE34248     GPL570     Paired LS and NLS               Mild to moderate plaque psoriasis                            14         Bigler *et al* ([@b11-mmr-20-01-0225])
  GSE41662     GPL570     Paired LS and NLS               Moderate to severe plaque psoriasis                          24         Bigler *et al* ([@b11-mmr-20-01-0225])
  GSE53552     GPL570     Paired LS and NLS               Moderate to severe plaque psoriasis                          24         Russell *et al* ([@b12-mmr-20-01-0225])
  GSE75343     GPL570     Paired scalp LS and scalp NLS   Moderate to severe plaque psoriasis with scalp involvement   13         Ruano *et al* ([@b13-mmr-20-01-0225])

LS, lesional skin; NLS, non-lesional skin.

###### 

DEGs in each GEO series.

  GEO series   No. of total DEGs   No. of upregulated DEGs   No. of upregulated DEGs
  ------------ ------------------- ------------------------- -------------------------
  GSE14905     1195                682                       513
  GSE30999     1979                1040                      939
  GSE34248     1670                854                       816
  GSE41662     2203                1073                      1130
  GSE53552     2220                1084                      1136

DEGs, differentially expressed genes.

###### 

GO analysis of upregulated genes associated with psoriasis.

  Term                                                      Count   Rich factor (%)   P-value       Functional group
  --------------------------------------------------------- ------- ----------------- ------------- ------------------
  GO:0006955 immune response                                39      16.04938272       4.38742E-13   BP
  GO:0007398 ectoderm development                           17      6.995884774       2.50742E-08   BP
  GO:0006952 defense response                               29      11.93415638       4.97398E-08   BP
  GO:0031424 keratinization                                 9       3.703703704       1.40384E-07   BP
  GO:0008544 epidermis development                          15      6.172839506       3.81508E-07   BP
  GO:0009611 response to wounding                           25      10.28806584       5.4487E-07    BP
  GO:0006954 inflammatory response                          18      7.407407407       4.12036E-06   BP
  GO:0030855 epithelial cell differentiation                12      4.938271605       4.1551E-06    BP
  GO:0030216 keratinocyte differentiation                   9       3.703703704       4.20155E-06   BP
  GO:0009913 epidermal cell differentiation                 9       3.703703704       8.13933E-06   BP
  GO:0006935 chemotaxis                                     12      4.938271605       1.83209E-05   BP
  GO:0001533 cornified envelope                             6       2.469135802       1.19845E-05   CC
  GO:0005576 extracellular region                           49      20.16460905       0.000143627   CC
  GO:0005615 extracellular space                            23      9.465020576       0.000294727   CC
  GO:0031262 Ndc80 complex                                  3       1.234567901       0.001187266   CC
  GO:0044421 extracellular region part                      25      10.28806584       0.004874319   CC
  GO:0005792 microsome                                      10      4.115226337       0.00688315    CC
  GO:0042598 vesicular fraction                             10      4.115226337       0.008255849   CC
  GO:0001772 immunological synapse                          3       1.234567901       0.008416898   CC
  GO:0000777 condensed chromosome kinetochore               5       2.057613169       0.009278963   CC
  GO:0000793 condensed chromosome                           7       2.880658436       0.010321628   CC
  GO:0008009 chemokine activity                             7       2.880658436       3.62741E-05   MF
  GO:0004867 serine-type endopeptidase inhibitor activity   9       3.703703704       3.72441E-05   MF
  GO:0042379 chemokine receptor binding                     7       2.880658436       5.23427E-05   MF
  GO:0004866 endopeptidase inhibitor activity               10      4.115226337       0.000171511   MF
  GO:0030414 peptidase inhibitor activity                   10      4.115226337       0.00025684    MF
  GO:0004252 serine-type endopeptidase activity             9       3.703703704       0.001273205   MF
  GO:0008236 serine-type peptidase activity                 9       3.703703704       0.003155874   MF
  GO:0017171 serine hydrolase activity                      9       3.703703704       0.003376462   MF
  GO:0005125 cytokine activity                              9       3.703703704       0.005452577   MF
  GO:0004175 endopeptidase activity                         13      5.349794239       0.005566809   MF

GO, gene ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

GO analysis of downregulated genes associated with psoriasis.

  Term                                                                 Count   Rich factor (%)   P-value    Functional group
  -------------------------------------------------------------------- ------- ----------------- ---------- ------------------
  GO:0044057 regulation of system process                              6       6.976744          0.008882   BP
  GO:0006940 regulation of smooth muscle contraction                   3       3.488372          0.010755   BP
  GO:0007517 muscle organ development                                  5       5.813953          0.011225   BP
  GO:0030003 cellular cation homeostasis                               5       5.813953          0.020798   BP
  GO:0051241 negative regulation of multicellular organismal process   4       4.651163          0.030364   BP
  GO:0055080 cation homeostasis                                        5       5.813953          0.03044    BP
  GO:0042698 ovulation cycle                                           3       3.488372          0.031344   BP
  GO:0006937 regulation of muscle contraction                          3       3.488372          0.035764   BP
  GO:0019432 triglyceride biosynthetic process                         2       2.325581          0.036656   BP
  GO:0008016 regulation of heart contraction                           3       3.488372          0.040411   BP
  GO:0005576 extracellular region                                      25      29.06977          0.00021    CC
  GO:0005615 extracellular space                                       12      13.95349          0.001648   CC
  GO:0044421 extracellular region part                                 14      16.27907          0.002814   CC
  GO:0031012 extracellular matrix                                      6       6.976744          0.047088   CC
  GO:0008092 cytoskeletal protein binding                              8       9.302326          0.009079   MF
  GO:0003779 actin binding                                             6       6.976744          0.018296   MF
  GO:0004857 enzyme inhibitor activity                                 5       5.813953          0.037901   MF
  GO:0003995 acyl-CoA dehydrogenase activity                           2       2.325581          0.068241   MF
  GO:0042803 protein homodimerization activity                         5       5.813953          0.07167    MF
  GO:0008201 heparin binding                                           3       3.488372          0.084388   MF
  GO:0030246 carbohydrate binding                                      5       5.813953          0.084603   MF

GO, gene ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

KEGG analysis of DEGs associated with psoriasis.

  Regulation      ID         Term                                        Count   Rich factor (%)   P-value      Genes
  --------------- ---------- ------------------------------------------- ------- ----------------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     hsa05164   Influenza A                                 11      4.280155642       0.00022787   IRF7, OAS3, CXCL8, IL1B, RSAD2, OAS1, OAS2, MX1, STAT1, TMPRSS4, CXCL10
  Upregulated     hsa05162   Measles                                     9       3.501945525       0.00073285   CCNE1, PRKCQ, IRF7, OAS3, IL1B, OAS1, OAS2, MX1, STAT1
  Upregulated     hsa04062   Chemokine signaling pathway                 10      3.891050584       0.00162187   CXCL1, CCL22, CCL20, CXCL13, CXCL9, CXCL8, CXCR2, STAT1, CCL18, CXCL10
  Upregulated     hsa05160   Hepatitis C                                 7       2.723735409       0.01355117   IFIT1, IRF7, OAS3, CXCL8, OAS1, OAS2, STAT1
  Upregulated     hsa05168   Herpes simplex infection                    8       3.112840467       0.01820027   CDK1, IFIT1, IRF7, OAS3, IL1B, OAS1, OAS2, STAT1
  Upregulated     hsa00240   Pyrimidine metabolism                       6       2.33463035        0.01847329   TYMP, NT5C3A, RRM2, UPP1, PNP, CMPK2
  Upregulated     hsa04620   Toll-like receptor signaling pathway        6       2.33463035        0.01989591   IRF7, CXCL9, CXCL8, IL1B, STAT1, CXCL10
  Upregulated     hsa05146   Amoebiasis                                  6       2.33463035        0.01989591   ARG1, CXCL8, IL1B, SERPINB4, SERPINB13, SERPINB3
  Upregulated     hsa01100   Metabolic pathways                          27      10.50583658       0.03117996   XDH, GDA, KYNU, HSD17B2, NT5C3A, GALNT6, CYP2C18, UPP1, AASS, PNP, CMPK2, ARG1, TYMP, HPSE, ALOX12B, FUT2, SPTLC2, DHRS9, HYAL4, ST6GALNAC1, SQLE, RRM2, AKR1B10, LIPG, GK, SMPD3, PLA2G4D
  Upregulated     hsa04110   Cell cycle                                  6       2.33463035        0.0359891    CCNB1, CCNE1, CDK1, CDC45, TTK, CDC20
  Upregulated     hsa04060   Cytokine-cytokine receptor interaction      8       3.112840467       0.05301106   CCL20, CXCL13, CXCL9, CXCL8, IL1B, CXCR2, IL7R, CXCL10
  Upregulated     hsa04623   Cytosolic DNA-sensing pathway               4       1.556420233       0.06819191   IRF7, IL1B, AIM2, CXCL10
  Upregulated     hsa04668   TNF signaling pathway                       5       1.945525292       0.07110534   CXCL1, NOD2, CCL20, IL1B, CXCL10
  Upregulated     hsa04115   p53 signaling pathway                       4       1.556420233       0.07600871   CCNB1, CCNE1, CDK1, RRM2
  Upregulated     hsa04622   RIG-I-like receptor signaling pathway       4       1.556420233       0.08420339   ISG15, IRF7, CXCL8, CXCL10
  Downregulated   hsa04960   Aldosterone-regulated sodium reabsorption   3       3.488372093       0.01441893   HSD11B1, NR3C2, ATP1A2
  Downregulated   hsa03320   PPAR signaling pathway                      3       3.488372093       0.03821865   ACOX2, LPL, ACADL

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.
